Helen Dinkelspiel1, Barbara Fetterman, Nancy Poitras, Walter Kinney, J Thomas Cox, Thomas Lorey, Philip E Castle. 1. 1Division of Gynecologic Oncology, Columbia University College of Physicians and Surgeons, New York, NY; 2Regional Laboratory, Kaiser Permanente Northern California, Berkeley, CA; 3Department of Women's Health and Division of Gynecologic Oncology, The Permanente Medical Group, Oakland, CA; 4University of California Santa Barbara (Retired), Santa Barbara, CA; and 5Albert Einstein College of Medicine, Bronx, NY.
Abstract
OBJECTIVE: Kaiser Permanente Northern California (KPNC) introduced 3-year Pap and human papillomavirus DNA cotesting for cervical cancer screening in women 30 years or older in 2003 to 2004. Patient and provider willingness to extend screening intervals and the impact on annual cervical cancer incidence after interval extension are evaluated. MATERIALS AND METHODS: Age-adjusted cervical cancer rates and screening intervals were calculated from KPNC Regional Laboratory databases and Northern California Cancer Registry from 2000 to 2009. RESULTS: The median screening interval between negative cotests was 36 months compared to the 16 months after a negative Pap test alone before the implementation of cotesting. The age-adjusted invasive cancer rate was 6.5 per 100,000 women in 2000 and 6.3 in 2009; there was no difference in the rates of cervical cancer in women 30 years or older from 2000 to 2009 (p(trend) = .7). CONCLUSIONS: Patients and providers were compliant with the extension of screening intervals with cotesting. Cervical cancer rates remained constant during the 10-year study period despite extending screening intervals after a negative cotest.
OBJECTIVE: Kaiser Permanente Northern California (KPNC) introduced 3-year Pap and human papillomavirus DNA cotesting for cervical cancer screening in women 30 years or older in 2003 to 2004. Patient and provider willingness to extend screening intervals and the impact on annual cervical cancer incidence after interval extension are evaluated. MATERIALS AND METHODS: Age-adjusted cervical cancer rates and screening intervals were calculated from KPNC Regional Laboratory databases and Northern California Cancer Registry from 2000 to 2009. RESULTS: The median screening interval between negative cotests was 36 months compared to the 16 months after a negative Pap test alone before the implementation of cotesting. The age-adjusted invasive cancer rate was 6.5 per 100,000 women in 2000 and 6.3 in 2009; there was no difference in the rates of cervical cancer in women 30 years or older from 2000 to 2009 (p(trend) = .7). CONCLUSIONS:Patients and providers were compliant with the extension of screening intervals with cotesting. Cervical cancer rates remained constant during the 10-year study period despite extending screening intervals after a negative cotest.
Authors: Ming Guo; Abha Khanna; Jianping Wang; Marilyn A Dawlett; Teresa L Kologinczak; Genevieve R Lyons; Roland L Bassett; Nour Sneige; Yun Gong; Therese B Bevers Journal: Cancer Cytopathol Date: 2017-05-12 Impact factor: 5.284
Authors: M Schiffman; R D Burk; S Boyle; T Raine-Bennett; H A Katki; J C Gage; N Wentzensen; J R Kornegay; C Aldrich; T Tam; H Erlich; R Apple; B Befano; P E Castle Journal: J Clin Microbiol Date: 2014-10-22 Impact factor: 5.948